38th week of 2020 patent applcation highlights part 25 |
Patent application number | Title | Published |
20200291026 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS - Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R | 2020-09-17 |
20200291027 | TETRACYCLIC BROMODOMAIN INHIBITORS - The present invention provides for compounds of formula (I) | 2020-09-17 |
20200291028 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A BENZOTRIAZOLE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR - Compounds having a structure according to formula (I) | 2020-09-17 |
20200291029 | CARBAPENEM COMPOUNDS - This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection. | 2020-09-17 |
20200291030 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES - Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases. | 2020-09-17 |
20200291031 | CRYSTAL FORM OF PARP-1 INHIBITOR AND PREPARATION METHOD THEREFOR - A crystal form of PARP-1 inhibitor and a preparation method therefor are described. Specifically, a crystal form A of 4-[[3-[[2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-α]pyrazine-7-yl]carbonyl]-4-fluorophenyl]methyl-1(2H)-phthalazinone (formula I) and a preparation method therefor are described. | 2020-09-17 |
20200291032 | PYRIMIDINE DERIVATIVES - The invention provides new pyrimidine compounds having the general formula (I), wherein R | 2020-09-17 |
20200291033 | IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE - The present invention relates to compounds of formula I | 2020-09-17 |
20200291034 | BRIDGED PIPERIDINE DERIVATIVES - The present invention relates to a compound of formula | 2020-09-17 |
20200291035 | SOLID FORMS OF A SYK INHIBITOR - Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized: | 2020-09-17 |
20200291036 | POLYMORPH OF RUCAPARIB CAMSYLATE AND PREPARATION METHOD THEREOF AND USE OF SAME - The present disclosure may disclose a new crystal form D of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl) methanesulfonic acid salt, preparation method therefor and a medicinal use. Compared to the existing crystalline forms, this new crystalline form has clear advantages with respect to solubility, stability, and the preparation process. | 2020-09-17 |
20200291037 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) - The disclosure is directed to compounds of Formula I | 2020-09-17 |
20200291038 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS - The invention provides novel compounds having the general formula (I) | 2020-09-17 |
20200291039 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS - Compounds of Formula I: | 2020-09-17 |
20200291040 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process. | 2020-09-17 |
20200291041 | PCSK9 Inhibitors and Methods of Use Thereof - The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein. | 2020-09-17 |
20200291042 | MACROCYCLE CONTAINING AMINOPYRAZOLE AND PYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (1), a pharmaceutical composition thereof, and a use thereof in inhibiting tropornyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk. | 2020-09-17 |
20200291043 | HETEROCYCLE DERIVATIVES AS PESTICIDES - The invention relates to novel compounds of the formula (I) | 2020-09-17 |
20200291044 | SENSOR FOR DETECTING GAS ANALYTE - A sensor and a method of using the sensor are disclosed. The sensor includes a conductive region in electrical communication with two electrodes, the conductive region including single-walled carbon nanotubes, nanosized particles of a metal dichalcogenide, and a mercaptoimidazolyl metal-ligand complex. The sensor can be used to detect volatile compounds that have a double or triple bond. | 2020-09-17 |
20200291045 | CONDUCTIVITY ENHANCEMENT OF MOFS VIA DEVELOPMENT OF MOFPOLYMER COMPOSITE MATERIAL - A method for enhancing the conductivity of MOF-5 by the development of an MOF-5 polymer composite material. The composite material incorporates a conductive polymer, preferably polyaniline, in the solvo-thermal synthesis pathway of MOF-5. The electrically conductive MOF-5 composite exhibits electric conductivity three orders of magnitude higher than that of MOF-5 while maintaining the crystallinity, robustness, and thermal stability of MOF-5. | 2020-09-17 |
20200291046 | PREPARATION METHOD FOR ZEOLITIC IMIDAZOLATE FRAMEWORKS - The present invention provides a preparation method for zeolitic imidazolate frameworks. The preparation method comprises: adding a metal carbonate or oxide, an organic ligand to a hydrophilic liquid to obtain a mixture; introducing an acidic gas to reach a reaction pressure of 0.1 MPa to 2.0 MPa, and reacting for a predetermined time; heating to 30° C.-60° C. and vacuuming to obtain the zeolitic imidazolate framework. The present invention also provides a zeolitic imidazolate framework obtained by the above preparation method. The preparation method according to the present invention is environmentally friendly and has a high yield. | 2020-09-17 |
20200291047 | Oral Care Compositions - Described herein are complexes comprising a cationic antibacterial agent and a metal salt; oral care compositions comprising same; along with methods of making and using these complexes and compositions. | 2020-09-17 |
20200291048 | PRODUCTION PROCESS FOR PHOSPHOETHANOLAMINE - A method for the production of phosphoethanolamine is disclosed. Phosphoric acid and monoethanolamine are mixed at a sufficient ratio using a doser to form a solution. The solution is then esterified by heating the solution to about 200° C., followed by cooling the solution to 40° C. A sufficient amount of distilled water is added to the solution to produce the desired viscosity. Excess ethanol is then filtered from the solution via a suction element. The solution is then subjected to centrifugal action for up to four hours at 1800 RPM to separate the phosphoethanolamine until a moisture content below 20% is reached. The remainder is then air dried to further isolate the phosphoethanolamine. | 2020-09-17 |
20200291049 | Radioactive Phospholipid Metal Chelates for Cancer Imaging and Therapy - Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula: | 2020-09-17 |
20200291050 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS - Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders. | 2020-09-17 |
20200291051 | COMPOSITIONS AND METHODS FOR STEREOREGULAR RING EXPANSION METATHESIS POLYMERIZATION - Disclosed are to metallocyclopropene complexes, methods of making same, methods for ring expansion metathesis polymerization, and polymers prepared by the methods for ring expansion metathesis polymerization. | 2020-09-17 |
20200291052 | BIS-PHENANTHROLINE IRON MACROCYCLE COMPLEX FOR OXYGEN REDUCTION REACTION - Disclosed are compounds, compositions, and methods useful for the oxygen reduction reaction (ORR) and capable of operating efficiently at low overpotentials. | 2020-09-17 |
20200291053 | METAL COMPLEX AS SENSOR COMPOUND FOR DETECTING GAS ANALYTE - A sensor compound and sensor composition comprising the sensor compound are disclosed. The sensor compound includes a metal atom and a mercaptoimidazolyl multidentate ligand. The sensor composition comprises the sensor compound and a metal dichalcogenide. | 2020-09-17 |
20200291054 | MOLECULES FROM SEAWEEDS WITH ANTI-CANCER ACTIVITY - The present invention provides purified compounds extracted from seaweeds having the formula (I): | 2020-09-17 |
20200291055 | Methods of Preparing Nicotinamide Riboside and Derivatives Thereof - Methods of preparing nicotinamide riboside and derivatives thereof. In an aspect, the invention relates to a method of preparing a compound of formula (I) | 2020-09-17 |
20200291056 | ACYL-PROTECTED L-LNA-GUANOSINE L-MONOMERS - The present invention relates to the field of stereodefined phosphorothioate oligonucleotidess and to nucleoside monomers and methods of synthesis thereof. Herein are disclosed acyl protected L-LNA-G monomers which have improved solubility and stability characteristics, and result in improved efficacy in oligonucleotide synthesis. | 2020-09-17 |
20200291057 | A Method for Polyalkoxylation of Nucleic Acids that Enables Recovery and Reuse of Excess Polyalkoxylation Reagent - The present invention is related to a method for the preparation of a modified nucleic acid molecule comprising a nucleic acid moiety and a non-nucleic acid moiety by reacting a first reactant and a second reactant, wherein the first reactant comprises the non-nucleic acid moiety and a carboxyl group, and wherein the second reactant is an amino-modified nucleic acid molecule comprising the nucleic acid moiety and an amino modification comprising an amino group which is attached to the nucleic acid moiety, wherein the method comprises the following steps: a) activating the first reactant, preferably the carboxyl group of the first reactant, by a condensation reagent in a water miscible organic solvent, and b) reacting the activated first reactant, preferably the activated carboxyl group of the first reactant, of step a) and the second reactant, preferably the amino group of the amino modification of the amino-modified nucleic acid molecule which has been dissolved in water or a mixture of a water miscible organic solvent and water, whereby the modified nucleic acid molecule is formed. | 2020-09-17 |
20200291058 | INHIBITORS OF GLUCOCORTICOID RECEPTOR - The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer. | 2020-09-17 |
20200291059 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS - Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 2020-09-17 |
20200291060 | NOVEL 7-DEHYDROCHOLESTEROL DERIVATIVES AND METHODS USING SAME - The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7DHC) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human. In other aspects, the present invention provides a method of preparing compounds of the invention, or a salt or solvate thereof. | 2020-09-17 |
20200291061 | METHOD FOR PRODUCING PEPTIDE COMPOUND - A method for producing a peptide by conducting steps (1) condensing an N-protected amino acid or an N-protected peptide to an N-terminus of a C-protected amino acid or a C-protected peptide represented by formula (II): | 2020-09-17 |
20200291062 | CORN PROTEIN RETENTION DURING EXTRACTION - Described herein is a method of maintaining corn protein yield during extraction, comprising obtaining a corn gluten material, washing the corn gluten material to remove non-protein components with an ethanol-water solvent comprising at least 85 wt % ethanol to obtain a corn protein concentrate product, wherein the loss of corn protein content during extraction is less than 25% of total corn protein. | 2020-09-17 |
20200291063 | METHOD FOR SEPARATION OF MONOMERIC POLYPEPTIDES FROM AGGREGATED POLYPEPTIDES - Herein is reported a method for obtaining a polypeptide in monomeric form comprising the steps of a) providing a solution comprising the polypeptide in monomeric form and in aggregated form, wherein the ratio of monomeric to aggregated form is 4:1 or less as determined by size exclusion chromatography, b) performing a mixed-mode chromatography in bind-and-elute mode, or a hydrophobic interaction chromatography in flow-through mode, or a size-exclusion chromatography, and c) performing a weak cation exchange chromatography in bind-and-elute mode or flow-through mode, and thereby obtaining the polypeptide in monomeric form. | 2020-09-17 |
20200291064 | PURIFICATION OF POLYPEPTIDES USING DUAL STAGE TANGENTIAL-FLOW ULTRAFILTRATION - The present invention is directed to methods for the separation of a molecule of interest from a solution containing the molecule using dual stage tangential-flow ultrafiltration (“TFF”). In particular, the methods of the invention are directed to the processing of crude feed streams such as conditioned cell culture supernatant to dramatically reduce contaminant and/or impurity levels prior to subsequent, i.e., downstream, refining unit operations. The methods of the invention may be used in the processing of a crude feed stream from biological production systems such as fermentation or other cell culture process, and may further eliminate the need for time consuming impurity precipitation (e.g., pH driven) and/or precipitate filtration processes prior to downstream processes that are sensitive to high impurity loads such as chromatographic unit operations. The disclosed dual stage TFF process combines at least two TFF unit operations that may be advantageously conducted at a pH that corresponds to or is about that of the pH of the feed stream, e.g., a cell culture supernatant, typically a pH of 7.5±1.0. The use of the TFF unit operations to supplement, improve or replace traditional processes for purification of proteins of interest for a feed stream may represent significant savings in both direct and indirect processing costs, For example, in addition to indirect savings by eliminating precipitation and precipitate filtration processes, the reduction in impurity loads effected by the dual stage TFF unit operations may result in indirect savings by improving downstream column performance, e.g., chromatographic separation, dynamic binding capacity, operational lifetime and/or a reduction of the required column size. In particular embodiments, the methods of the invention are used in processes for the purification of immunoglobulin molecules, e.g., antibodies, which processes are devoid of affinity purification steps, e.g., protein A affinity chromatography purification. | 2020-09-17 |
20200291065 | COMPOSITIONS AND METHODS FOR REMOVAL OF DETERGENTS FROM AQUEOUS SOLUTIONS - Compositions and methods are described in which a primary detergent or surfactant in an aqueous solution is removed by the addition of a secondary detergent or surfactant in concentrations that exceed the critical micellar concentration (CMC) of the secondary detergent or surfactant. These compositions and methods are particularly applicable to protein-containing solutions. Typical primary detergents/surfactants include polysorbate 20, polysorbate 80, and Triton X-100. Suitable secondary detergents or surfactants can be ionic, nonionic, or zwitterionic. Typical secondary detergents/surfactants include, but are not limited to, galactoside detergents (e.g. octyl-β-galactoside), glucamide detergents (e.g. MEGA 8, MEGA 9, MEGA 10), cholamide detergents (e.g. CHAPS, CHAPSO, BIGCHAPS), and sulfobetaine detergents (such as sulfobetaine 3-10). | 2020-09-17 |
20200291066 | IL-2RBETA BINDING COMPOUNDS - IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists. | 2020-09-17 |
20200291067 | IL-2RGAMMA BINDING COMPOUNDS - IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists. | 2020-09-17 |
20200291068 | POLYPEPTIDES INCLUDING A BETA-TRICALCIUM PHOSPHATE-BINDING SEQUENCE AND USES THEREOF - Provided herein are polypeptides that include one or more β-tricalcium phosphate (βTCP)-binding sequence(s) and uses thereof. | 2020-09-17 |
20200291069 | IMMUNOMODULATORS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 2020-09-17 |
20200291070 | BICYCLIC PEPTIDYL INHIBITORS - The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the IκB kinase α/β (IKKα/β)-binding domain of NF-kB essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKKb interaction, thereby selectively inhibiting canonical NF-kB signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells. | 2020-09-17 |
20200291071 | GLYCOPEPTIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME, AND USES THEREOF - Disclosed herein are novel compounds and uses thereof. The present compounds are useful in suppressing the growth of various bacteria, including gram-positive and gram-negative bacteria. Accordingly, these compounds may be used to manufacture a medicament or pharmaceutic composition for treating disease and/or disorders associated with bacterial infection, especially antibiotic-resistant bacterial infection. Al so disclosed herein are methods for treating infectious diseases by use of the present compounds, medicament or pharmaceutical composition. | 2020-09-17 |
20200291072 | CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS - Disclosed is a new class of conjugated virus-like particles (VLPs). These conjugated VLPs bind a wide variety of tumors and comprise epitopes recognized by a prior T cell immune response already existing in a host. These epitopes are derived from pathogens or previous vaccinations (such as early childhood vaccines). This provokes the body's pre-existing cytotoxic immunity obtained through previous infection or previous childhood vaccination to be redirected to the tumor cells for the elimination of cancer, and form long-term anti-tumor immunity. The described conjugated VLPs are useful for tailoring a broad range of tumors towards a response from existing immunity circumventing the need to identify tumor antigens or generate tumor-specific immune responses. Importantly, the compositions and methods described herein broadens opportunities for treatment for all cancer types in subjects who previously had un-targetable cancers due to various technological and biological limitations of currently available immuno-therapeutic drugs. | 2020-09-17 |
20200291073 | CATIONIC NEUROTOXINS - Method for preventing or treating a condition or disease in a subject comprising administering to the subject an engineered clostridial toxin comprising at least one amino acid modification that increases the isoelectric point of the toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification. | 2020-09-17 |
20200291074 | CHANNELRHODOPSINS FOR OPTICAL CONTROL OF CELLS - The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels. | 2020-09-17 |
20200291075 | Light-Responsive Fusion Proteins For Controlling Binding To Targets - Provided herein is an isolated fusion protein comprising a light-responsive domain and a heterologous peptide component. Exposure of the fusion protein to light induces a conformational change in the fusion protein that alters an activity of the fusion protein and the activity is a binding activity selected from an in vitro binding activity, an in vivo extracellular binding activity and an in vivo intracellular binding activity. Also provided are methods of using and identifying the fusion proteins. | 2020-09-17 |
20200291076 | COMPOSITIONS AND METHODS FOR TARGETING MASAS TO TREAT CANCERS WITH SPICEOSOME MUTATIONS - The present disclosure relates to compositions and methods for treating cancers. In particular, the present disclosure provides materials and methods for identifying mis-splicing-associated surface antigens (MASAs) generated by altered spliceosome proteins, as well as materials and methods for targeting cancerous tumors expressing MASAs. | 2020-09-17 |
20200291077 | POROUS MICROSPHERES INCLUDING MUSSEL ADHESIVE PROTEIN, AND METHOD FOR MANUFACTURING SAME - The present invention relates to a porous microsphere comprising a mussel adhesive protein and a method of preparing the same. The porous microsphere comprising the mussel adhesive protein according to the present invention is capable of minimally invasive bio-injection through syringes to efficiently deliver therapeutic stem cells to the sites of tissue defects as cell carriers. Further, the present invention may be widely applied to scaffolds for tissue engineering, drug carriers, or the like, which may be suitably applied to the size of the defected site of tissue. | 2020-09-17 |
20200291078 | METHOD OF MAKING RECOMBINANT SILK AND SILK-AMYLOID HYBRID PROTEINS USING BACTERIA - Methods of making recombinant secretion of silk and silk-amyloid proteins using bacteria are provided. | 2020-09-17 |
20200291079 | ENGINEERING STRUCTURALLY DEFINED NON-SACCHARIDE GLYCOSAMINOGLYCAN MIMETICS VIA A POLYPROLINE SCAFFOLD - A non-saccharide glycosaminoglycan mimetic molecule comprising a polyproline backbone and one or more non-saccharide molecules, wherein the non-saccharide molecules are bound to one or more prolines and/or proline derivatives on the polyproline backbone, is disclosed herein. In a preferred embodiment the non-saccharide molecule is a negatively charged sulfate. The invention also relates to methods of synthesizing said non-saccharide glycosaminoglycan mimetic molecule and the use of the molecules thereof in targeting cell adhesion molecules such as selectin. | 2020-09-17 |
20200291080 | Recombinase Purification - The invention is the products and methods associated with purifying overexpressed recombinant recombinases from a host cell line resulting in an un-tagged protein of interest without any additional, non-native amino acids. The invention employs at least one DNA vector that co-expresses a tagged fusion protein and the recomibinase protein with the recombinase protein having an affinity for binding to the the tagged fusion protein. Isolation methods of the recominbase protein include the targeting of the tagged fusion protein. | 2020-09-17 |
20200291081 | NOVEL RECEPTORS FOR CYCLIC DINUCLEOTIDES AND METHODS AND KITS FOR SCREENING AGONISTS OR INHIBITORS THEREOF - Disclosed herein is a recombinant vector being capable of expressing a novel receptor that senses exogenous cyclic dinucleotides (subtype M of STING) and meanwhile disclosed herein are a method and a kit for specifically identifying and detecting the expression of the said receptor. Further, provided herein are a medicament screening model and a kit for screening agonists or inhibitors targeting subtype M of the novel gene STING and the use thereof. Use of the screening model and the kit could simplify the screening procedure, enhance the screening efficiency and expand the range of the medicaments to be screened. | 2020-09-17 |
20200291082 | PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST-DISEASE WITH DEFENSINS - The present invention relates to methods for treatment and/or prevention of acute as well as chronic graft-versus-host-disease (GVHD), and in particular to methods for decreasing mortality and increasing especially long term survival; acute complications associated with GVHD such as diarrhea, weight loss and sepsis based on normalization of gut, liver, lung and skin microbiota and mucosal defense; rebalance of the immune system with normalization of cytokine production of IFN-γ, TNF-α, 11-4, IL-5, IL-6, IL-8, IL-9, IL-10 and IL-13 and prevention and/or treatment of cytokine storm; chronic complications associated with GVHD such as bronchiolitis obliterans and scleroderma, the method comprising oral, subcutaneous, intrapulmonary and/or dermal/transdermal administration of one or more mammalian defensins selected from the group of α- and β-defensins in a patient that has or is about to receive an allogeneic hematopoietic stem cell transplantation. | 2020-09-17 |
20200291083 | ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT - The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis. | 2020-09-17 |
20200291084 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-09-17 |
20200291085 | FUSION PROTEINS FOR TREATING CANCER AND RELATED METHODS - Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer | 2020-09-17 |
20200291086 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS - Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: | 2020-09-17 |
20200291087 | ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS - Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated. | 2020-09-17 |
20200291088 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-09-17 |
20200291089 | MULTIFUNCTIONAL MOLECULES COMPRISING A TRIMERIC LIGAND AND USES THEREOF - Disclosed herein are novel multifunctional, e.g., bifunctional, or trifunctional, molecules (e.g., fusion polypeptides or nucleic acids) that include a trimeric ligand, and optionally, an immunoglobulin constant domain, as well as methods of making and using the multifunctional molecules, e.g., for treating cancer. | 2020-09-17 |
20200291090 | CONSTITUTIVELY ACTIVE CHIMERIC CYTOKINE RECEPTORS - Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein. | 2020-09-17 |
20200291091 | Compositions and Methods for Immunomodulation in an Organism - The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo. | 2020-09-17 |
20200291092 | CONCEPT FOR THE TREATMENT OF MONOGENETIC DISORDERS - The present invention relates to a nucleic acid expression cassette, in particular for the expression of a human liver-specific and/or liver-expressed protein and/or preferably physiologically active domains and/or fragments thereof in a patient suffering from a monogenetic disorder caused by a mutation in the gene coding for the liver-specific and/or liver-expressed protein. | 2020-09-17 |
20200291093 | IMPROVED PEPTIDE EXPRESSION AND APO-H SPECIFIC SUBJECT ANTIBODY DETECTION - Provided herein are compositions, systems, kits, and methods for expressing a peptide of interest, such as Apolipoprotein H (ApoH), also known as β2-glycoprotein I (β2GPI), at increased levels using a non-ApoH signal peptide (e.g., a signal peptide that permits increased protein export from cells). Also provided herein are compositions, systems, kits, and methods for employing such recombinant ApoH with a non-ApoH signal peptide to detect subject Apolipoprotein H antibodies in a sample from a subject (e.g., to diagnose antiphospholipid syndrome in a subject). | 2020-09-17 |
20200291094 | FIBRONECTIN TYPE III DOMAIN BASED SCAFFOLD COMPOSITIONS, METHODS AND USES - A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications. | 2020-09-17 |
20200291095 | METHOD FOR PROMOTING WOUND HEALING - The present invention discloses a method for treating wounds and for accelerating the healing of wounds by administering an effective amount of a pharmaceutical composition containing type VII collagen protein, mini-C7 protein, variants thereof or any combinations thereof. The pharmaceutical composition may be administered through a variety of routes including intravenous injection, topical application, or oral ingestion. The method may further include administering a genetically modified fibroblast capable of expressing type VII collagen protein, miniC7 protein, variants thereof or small growth factors to achieve synergistic healing effect. | 2020-09-17 |
20200291096 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2020-09-17 |
20200291097 | MULTISTEP FINAL FILTRATION - Herein is reported a method for the final filtration of concentrated polypeptide solutions comprising the combination of two immediately consecutive filtration steps with a first filter of 3.0 μm and 0.8 μm pore size and a second filter of 0.45 μm and 0.22 μm pore size. | 2020-09-17 |
20200291098 | ANTIBODY, COMPOSITE, DETECTION DEVICE AND METHOD USING SAME - The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains: | 2020-09-17 |
20200291099 | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES - Anti-SpA murine, chimeric and humanized monoclonal antibodies, and variant antibodies having a heavy chain with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections. | 2020-09-17 |
20200291100 | TREATMENT OF AGE-RELATED AND MITOCHONDRIAL DISEASES BY INHIBITION OF HIF-1 ALPHA FUNCTION - Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods. | 2020-09-17 |
20200291101 | Novel Treatment Method for Cockayne Syndrome - Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody either a mTOR antigen or a DAP1 in a bodily fluid such as blood, creating an antibody-antigen complex, removing antibody-antigen complex from the bodily fluid, and returning the purified bodily fluid to the CS patient. | 2020-09-17 |
20200291102 | METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN - A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal. | 2020-09-17 |
20200291103 | CELL CULTURE MEDIA AND METHODS OF ANTIBODY PRODUCTION - Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided. | 2020-09-17 |
20200291104 | ANTIBODY MOLECULES WHICH BIND TNF ALPHA - The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2020-09-17 |
20200291105 | NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF - Disclosed are compositions and methods related to IL-25 binding molecules. | 2020-09-17 |
20200291106 | Novel Anti-IL13 Antibodies and Uses Thereof - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 2020-09-17 |
20200291107 | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions - Methods of manufacture for producing anti-IL-12/IL-23p40 antibodies, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab, in CHO and specific pharmaceutical compositions of the antibody are useful in treating various diseases. | 2020-09-17 |
20200291108 | POLYPEPTIDES - There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification. | 2020-09-17 |
20200291109 | Composition to induce bone marrow stem cell mobilization - A pharmaceutical composition to induce bone marrow stem cell mobilization from the bone marrow to peripheral blood in patients suffering from pathological conditions, such as diabetes, or subjected to treatments that impair cell mobilization, or in patients suffering from the so called “poor mobilizer” condition, includes at least one therapeutic agent that inhibits production and/or action of the human cytokine oncostatin M (OSM), a macrophage derived factor that prevents mobilization of stem cells. | 2020-09-17 |
20200291110 | METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS - The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-γ levels. | 2020-09-17 |
20200291111 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER - The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer. | 2020-09-17 |
20200291112 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY - The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of A33 protein. The antibodies of the present technology are useful in methods for detecting and treating an A33-positive cancer in a subject in need thereof. | 2020-09-17 |
20200291113 | ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF - The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2020-09-17 |
20200291114 | ANTI-CD47 ANTIBODIES AND METHODS OF USE - Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors. | 2020-09-17 |
20200291115 | COMPOSITIONS AND METHODS FOR TREATING DISEASES - An engineered, non-naturally occurring molecule for target immunotherapy, comprising: (a) a first binding component capable of binding to a T cell; and (b) a second binding component capable of binding to a diseased cell. | 2020-09-17 |
20200291116 | ANTIBODIES AND METHODS OF USE THEREOF - Disclosed herein are methods and compositions for targeting a complex comprising a neoantigen presenting protein and a neoantigen in cancer. Further disclosed herein are antibodies that selectively bind to a complex comprising a neoantigen presenting protein and a neoantigen, as well as methods of use thereof. | 2020-09-17 |
20200291117 | ANTI-CTLA4 ANTIBODIES AND USES THEREOF - This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof. | 2020-09-17 |
20200291118 | ANTI-PD-1/CD47 BISPECIFIC ANTIBODY AND APPLICATION THEREOF - The present invention provides a recombinant protein. The recombinant protein includes an anti-PD-1 antibody and human SIRPA extracellular domain. The N-terminus of the human SIRPA extracellular domain is linked to the C-terminus of the heavy chain of the anti-PD-1 antibody. | 2020-09-17 |
20200291119 | ANTI-PD-L1 ANTIBODIES AND METHODS OF USING THE SAME FOR DETECTION OF PD-L1 - The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a N detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry. | 2020-09-17 |
20200291120 | ANTI-CLEC2D ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure relates to novel anti-CLEC2D antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases. | 2020-09-17 |
20200291121 | ANTI-IL-5RAlpha MONOCLONAL ANTIBODY - The present invention relates to biotechnology and provides antibodies that specifically bind to IL-5Rα. The invention also relates to DNA encoding said antibodies, the corresponding expression vectors and methods of production thereof, as well as methods of treatment using said antibodies. | 2020-09-17 |
20200291122 | TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIES - Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of an anti-GITR antibody alone or together with an anti-PD-1 or anti-PD-L1 antibody. | 2020-09-17 |
20200291123 | NOVEL ANTI-CD40 ANTIBODIES AND USE THEREOF - The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection. | 2020-09-17 |
20200291124 | BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF - CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions. | 2020-09-17 |
20200291125 | CHIMERIC ANTIGEN RECEPTORS, COMPOSITIONS, AND METHODS - This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK) cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a chimeric antigen receptor, and methods involving such chimeric antigen receptors. Generally, the chimeric antigen receptor includes an ectodomain that includes an antigen recognition region, a transmembrane domain linked to the ectodomain, and an endodomain linked to the transmembrane domain. The endodomain can include a signaling peptide that activates an NK cell. | 2020-09-17 |